NVIDIA at Crossroads: Will $116 Hold as the New Support? Jan. 3
421
Technical Analysis: * Trend Overview: NVDA has recently broken below the short-term support trendline, aligning with a bearish pattern. The stock is testing a critical support zone around $116, with declining momentum.
* Key Indicators: * MACD: Bearish crossover with increasing negative divergence indicates selling pressure. * Stoch RSI: Currently near oversold levels, showing possible consolidation or a short-term bounce.
* Volume: Rising sell volume signals strong bearish conviction as the price approaches key support.
Support and Resistance Levels: * Immediate Support: $116 (critical level). * Secondary Support: $110 (aligned with the next significant demand zone).
* Resistance Levels: * Near-term resistance at $124. * Further resistance at $128.95 and $149.10 (as noted by the CALL wall).
Options and GEX Analysis:
* Highest Positive GEX Level: $128.95, serving as the next potential gamma resistance. * PUT Dominance: Significant PUT support around $116 aligns with technical support, offering a strong defensive zone.
* Volatility Metrics: * IVR: 70.4% (indicating above-average implied volatility). * Options Flow: 41.4% CALLs dominance suggests a lack of bullish sentiment, though potential for a rebound remains.
Scenarios: 1. Bullish: * Entry: Above $124 on strong momentum. * Target: $128.95 or higher if the gamma squeeze accelerates. * Stop Loss: Below $120.
2. Bearish: * Entry: On a breakdown below $116 with strong volume. * Target: $110 or lower. * Stop Loss: Above $118.
Conclusion: NVDA is testing a critical support zone. A break below $116 could intensify the bearish momentum, while holding this level might attract short-term buyers aiming for $124+. Options data suggests bearish sentiment dominates, yet watch for unusual activity at support.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.